Compare ANGI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANGI | CRVS |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.0M | 459.0M |
| IPO Year | 2017 | 2016 |
| Metric | ANGI | CRVS |
|---|---|---|
| Price | $12.02 | $8.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $18.20 | $13.75 |
| AVG Volume (30 Days) | ★ 1.3M | 969.0K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.43 | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $1,057,636,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.89 | N/A |
| P/E Ratio | $16.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.25 | $2.54 |
| 52 Week High | $20.70 | $9.32 |
| Indicator | ANGI | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 50.25 | 47.57 |
| Support Level | $11.20 | $8.49 |
| Resistance Level | $11.61 | $9.17 |
| Average True Range (ATR) | 0.41 | 0.53 |
| MACD | 0.25 | -0.07 |
| Stochastic Oscillator | 96.98 | 16.56 |
Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).